What Does TransCode Therapeutics ($RNAZ) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks & Headquarters at a Glance
TransCode (RNAZ) is a small-cap RNA biotech targeting metastatic solid tumors with TTX-MC138, a miR-10b inhibitor. The Phase 2a launch and its cash runway are the key variables.
Subscribe🏢 What kind of company is TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is a clinical-stage RNA therapeutics biotech headquartered in Boston, Massachusetts, USA, and is listed on Nasdaq as a small-cap stock. The company's core strategy is to inhibit microRNA-10b (miR-10b), known to act as a switch for cancer metastasis, thereby blocking the growth and spread of metastatic solid tumors.
The lead candidate is TTX-MC138, a first-in-class therapeutic that inhibits the function of miR-10b. In the Phase 1a trial, it established the recommended Phase 2 dose without any dose-limiting toxicity (DLT) and generated an early signal that 44% of patients maintained stable disease for four months or longer. Beyond this, the company also has its own RNA therapeutics platform that leverages targets beyond miR-10b to induce immune responses.
How does it make money?| Business Segment | Revenue Mix | Description |
|---|---|---|
| Product Revenue | None | As a clinical-stage company, it has no commercialized in-house therapeutics |
| TTX-MC138 (Metastatic Solid Tumors) | Core Value Driver | Phase 1a completed; recommended Phase 2 dose established. Phase 2a dose-expansion trial planned within the Quantum Leap PRE-I-SPY platform |
| ctDNA-Positive Colorectal Cancer Cohort | Early Target | Phase 2a design enrolling up to 45 colorectal cancer patients who test ctDNA-positive after completing standard treatment |
| Immune & Glioblastoma Expansion | Platform Expansion | Includes positive preclinical data in glioblastoma, along with additional immune-activating RNA therapeutic programs |
Given its clinical-stage biotech profile, TransCode Therapeutics essentially has no in-house revenue ($0.0M), and most of its expenses are allocated to R&D and general administrative costs. Rather than traditional metrics such as revenue growth (-) or profit margin (-), far more important indicators are Phase 2a initiation and progress, ctDNA biomarker data, cash runway, and partnerships.
📐 Market Cap and Company Size
Market cap is around $30.1M, equivalent to About 0% of Samsung Electronics' market cap. The company has 12 people employees.
By market capitalization ($30.1M), TransCode Therapeutics is a very small micro-cap biotech. It has a history of repeated capital raises, reverse stock splits, and warrants, making its share price extremely volatile. Liquidity is limited, so a single piece of clinical or IR news can trigger sharp rallies or sell-offs.
📈 TransCode Therapeutics Outlook and Price Action
1-Year Price Performance
Analyst Consensus
52-Week Price RangeTransCode Therapeutics' medium- to long-term story hinges on a novel approach of blocking metastasis through miR-10b inhibition and on whether the Phase 2a trial within Quantum Leap's PRE-I-SPY platform succeeds. Metastasis is the leading cause of death in most solid tumors, yet there are very few approved therapies that target the metastatic process itself, creating substantial unmet medical need. miR-10b is a target gaining significant academic attention as a candidate metastasis switch.
On the other hand, the RNA therapeutics space is occupied by much larger players with greater capital, technology, and pipelines, such as Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Moderna (MRNA). The concept of metastasis-targeting therapy itself faces significant hurdles before clinical validation. Earnings per share ($-50.69) and return on equity (-59.3%) are not meaningful metrics; cash runway and clinical events are the core drivers of enterprise value.
⚔️ Core Competitive Strengths and Risks
TransCode Therapeutics has a differentiated RNA therapeutic concept targeting miR-10b, but it is a high-volatility small-cap biotech that simultaneously carries the high failure risk inherent in early clinical stages and the risk of repeated capital raises.
💪 Core Competitive Strengths
⚠️ Core Risks
🔄 Competitors and Related Stocks (Beneficiaries)
Representative related stocks in the RNA therapeutics and metastasis space include large-cap RNA companies such as Alnylam (ALNY), Ionis (IONS), Arrowhead Pharma (ARWR), and Moderna (MRNA). Major oncology-focused pharmaceutical companies such as Merck (MRK), BMS (BMY), and Eli Lilly (LLY) also tend to move together with the metastasis and immuno-oncology theme, grouping with small-cap RNA and oligo names to shape sector flow.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 ATYR | Atyr Pharma Inc | $0.46 | -5.2% | $44.7M | - | 0.9 | -98.37% | - |
 MGX | Metagenomi Therapeutics Inc | $1.15 | -0.9% | $43.4M | - | 0.4 | -60.61% | - |
 CNTX | Context Therapeutics Inc | $0.37 | -1.1% | $34.2M | - | 0.9 | -76.14% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | $258.01 | -0.8% | $34.5B | 43.6 | 25.5 | 100.7% | - |
| MRNA | Moderna Inc | $135.61 | -3.4% | $54.1B | - | 8.0 | -39% | - |
 CRSP | CRISPR Therapeutics AG | $53.45 | -2.4% | $5.2B | - | 3.0 | -26.09% | - |
✅ Investor Checkpoints
TransCode Therapeutics is a high-risk, high-reward small-cap RNA therapeutics company focused on early-stage clinical development. Be sure to review the following checkpoints before making an investment decision.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 🧪 Phase 2a Launch & Progress | Follow the launch timing and patient enrollment progress of the Phase 2a dose-expansion trial within the PRE-I-SPY platform. | Check clinical disclosures |
| 🔬 ctDNA Biomarker Data | Verify what changes TTX-MC138 drives in biomarkers and disease stage within the ctDNA-positive colorectal cancer patient group. | Follow conference & IR disclosures |
| 💵 Cash Runway & Dilution | Always check quarterly cash balances and the degree of share dilution caused by ATM offerings, public offerings, and warrant exercises. | Review quarterly financials |
| 🌐 Additional Pipeline Expansion | Whether expansion programs such as glioblastoma and immune RNA therapeutics advance into preclinical or clinical stages is central to platform value. | Monitor R&D updates |
Clinical failures, regulatory delays, share dilution from repeated capital raises, reverse stock splits or listing requirement issues, and improved data from large competing RNA therapeutics programs can all have a critical impact on the stock price. In addition, commercial validation of the metastasis-targeting therapy concept could take a considerable amount of time.
TransCode Therapeutics is a small-cap biotech with a differentiated RNA therapeutic concept aimed at blocking cancer metastasis by targeting miR-10b. The potential is intriguing, but clinical, financial, and competitive risks are very large, so an approach that strictly limits portfolio weighting and reviews clinical and capital events every quarter is warranted.
Check out US Stock Today's real-time dashboard to see TransCode Therapeutics' live quotes, technical indicators, and peer comparisons at a glance.
Subscribe Today's 5 AI picks, all free